

## Appendix A: Key to Acronyms

Updated: December 06, 2023

Reviewed: December 06, 2023

### Drug Name Abbreviations

<b><i>Acronym/Abbreviation</i></b>	<b><i>Definition</i></b>
3TC	lamivudine
ABC	abacavir
ATV	atazanavir
ATV/c	atazanavir/cobicistat
ATV/r	atazanavir/ritonavir
BIC	bictegravir
CAB	cabotegravir
CAB-LA	cabotegravir long-acting
COBI or c	cobicistat
d4T	stavudine
ddI	didanosine
DLV	delavirdine
DOR	doravirine
DRV	darunavir
DRV/c	darunavir/cobicistat
DRV/r	darunavir/ritonavir
DTG	dolutegravir
EFV	efavirenz
ETR	etravirine
EVG	elvitegravir
EVG/c	elvitegravir/cobicistat

FPV	fosamprenavir
FPV/r	fosamprenavir/ritonavir
FTC	emtricitabine
FTR	fostemsavir
IBA	ibalizumab
IDV	indinavir
<b>LEN</b>	<b>lenacapavir</b>
LPV	lopinavir
LPV/r	lopinavir/ritonavir
MVC	maraviroc
NFV	nelfinavir
NVP	nevirapine
R5	CCR5-utilizing virus
RAL	raltegravir
RPV	rilpivirine
RTV or r	ritonavir
SQV	saquinavir
T-20	enfuvirtide
TAF	tenofovir alafenamide
TDF	tenofovir disoproxil fumarate
TFV	tenofovir
TFV-DP	tenofovir-diphosphate
TMP-SMX	trimethoprim-sulfamethoxazole
TMR	temsavir
TPV	tipranavir
TPV/r	tipranavir/ritonavir
ZDV	zidovudine

## General Terms

<b><i>Acronym/Abbreviation</i></b>	<b><i>Definition</i></b>
17-BMP	beclomethasone 17-monopropionate
ACA	Affordable Care Act
ADAP	AIDS Drug Assistance Program
Ag/Ab	antigen/antibody
Al	aluminum
ALT	alanine aminotransferase
AMP	average manufacturer price
ART	antiretroviral therapy
ARTAS	Anti-Retroviral Treatment and Access to Services
ARV	antiretroviral
ASP	average sales price
AST	aspartate aminotransferase
AUC	area under the curve
AUD	alcohol use disorder
AUDIT-C	Alcohol Use Disorders Identification Test-Consumption
AV	atrioventricular
AWP	average wholesale price
AYA	adolescents and young adults
BMD	bone mineral density
BUN	blood urea nitrogen
Ca	calcium
CaCO <sub>3</sub>	calcium carbonate
CBC	complete blood count
CCB	calcium channel blockers

CD4	CD4 T lymphocyte
CDC	Centers for Disease Control and Prevention
CHF	congestive heart failure
CI	confidence interval capsid inhibitor
CKD	chronic kidney disease
Cl	chloride
C <sub>max</sub>	maximum plasma concentration
C <sub>min</sub>	minimum plasma concentration
CMV	cytomegalovirus
CNS	central nervous system
COC	combined oral contraceptive
CPI-U	consumer price index-urban
CPK	creatine phosphokinase
Cr	creatinine
CrCl	creatinine clearance
CSF	cerebrospinal fluid
CV	cardiovascular
CVD	cardiovascular disease
CYP	cytochrome P450
D/M	dual/mixed
DAA	direct-acting antiviral
DHA	dihydroartemisinin
DILI	drug-induced liver injury
DM	diabetes mellitus
DMPA	depot medroxyprogesterone acetate
DOT	directly observed therapy

EBV	Epstein-Barr virus
ECG	electrocardiogram
eGFR	estimated glomerular filtration rate
ESRD	end stage renal disease
FCP	federal price ceiling
FDA	U.S. Food and Drug Administration
FDC	fixed-dose combination
Fe	iron
FUL	federal upper limit
GAHT	gender-affirming hormone therapy
GHB	gamma-hydroxybutyrate
GI	gastrointestinal
gp	glycoprotein
GS	Gilead Sciences
H2	histamine 2
H2RA	H2 receptor antagonist
HAD	HIV-associated dementia
HAND	HIV-associated neurocognitive disorder
HAV	hepatitis A virus
HbA1C	hemoglobin A1c
HBcAb	hepatitis B core antibody
HBeAg	hepatitis B e antigen
HBsAb	hepatitis B surface antibody
HBsAg	hepatitis B surface antigen
HBV	hepatitis B virus
HCC	hepatocellular carcinoma
HCO <sub>3</sub>	bicarbonate

HCV	hepatitis C virus
HD	hemodialysis
HDL	high-density lipoprotein
HHS	U.S. Department of Health and Human Services
HIV	human immunodeficiency virus
HIV RNA	HIV viral load
HIV-1	human immunodeficiency virus type 1
HIV-2	human immunodeficiency virus type 2
HIVMA/IDSA	HIV Medicine Association of the Infectious Diseases Society of America
HLA	human leukocyte antigen
HMG-CoA	hydroxy-methylglutaryl-coenzyme A
HR	hazard ratio
HRSA	Health Resources and Services Administration
HRT	hormone replacement therapy
hs-CRP	high-sensitivity C-reactive protein
HSR	hypersensitivity reaction
HTLV-1	human T-lymphotropic virus-1 type I
IAS–USA	International AIDS Society–USA
IC <sub>50</sub>	inhibitory concentration
IL	interleukin
IM	intramuscular
IN	integrase
INR	international normalized ratio
INSTI	integrase strand transfer inhibitor
IPT	isoniazid preventive therapy
IRIS	immune reconstitution inflammatory syndrome

ISR	injection site reactions
IUD	intrauterine device
IV	intravenous
K	potassium
LA-ART	long-acting ART
LAI	long-acting injectable
LDL	low-density lipoprotein
LGBTQ	lesbian, gay, bisexual, transgender, or queer
LLOD	lower limits of detection
LTBI	latent tuberculosis infection
MAC	Mycobacterium avium complex
MAT	medication-assisted treatment
MATE	multidrug and toxin extrusion transporter
MDR	multidrug resistant
MDR-TB	multidrug-resistant tuberculosis
MDMA	methylenedioxymethamphetamine
MDRP	Medicaid Drug Rebate Program
MET	motivational enhancement therapy
Mg	magnesium
MHC	major histocompatibility complex
MI	motivational interviewing
MI	myocardial infarction
MPA	medroxyprogesterone acetate
MRI	magnetic resonance imaging
MSM	men who have sex with men
MTR	multi-tablet regimen
N/A	not applicable

Na	sodium
NA-ACCORD	North American AIDS Cohort Collaboration on Research and Design
NIH	National Institutes of Health
NNRTI	non-nucleoside reverse transcriptase inhibitor
NRTI	nucleoside/nucleotide reverse transcriptase inhibitor
NTD	neural tube defect
OARAC	Office of AIDS Research Advisory Council
OAT	opioid agonist therapy
OATP	organic anion-transporting polypeptide
<b>OBR</b>	<b>optimized background regimen</b>
OCT2	organic cation transporter 2
OH-itraconazole	active metabolite of itraconazole
OI	opportunistic infection
ONDCP	Office of National Drug Control Policy
OR	odds ratio
OTP	opioid treatment program
OD	opioid use disorder
P	phosphorus
P-gp	p-glycoprotein
PAH	pulmonary arterial hypertension
PBM	pharmacy benefit manager
PCP	Pneumocystis jirovecii pneumonia
PCR	polymerase chain reaction
PDE5	phosphodiesterase type 5
PHQ-2	Patient Health Questionnaire-2
PEP	post-exposure prophylaxis
PI	protease inhibitor



PI/c	cobicistat-boosted protease inhibitor
PI/r	ritonavir-boosted protease inhibitor
PK	pharmacokinetic
PO	orally
PPI	proton pump inhibitor
PR	protease
PrEP	pre-exposure prophylaxis
PTH	parathyroid hormone
QTc	QT corrected for heart rate
REPC	Retention through Enhanced Personal Contact
RNA	ribonucleic acid
RT	reverse transcriptase
RWHAP	Ryan White HIV/AIDS Program
SAMHSA	Substance Abuse and Mental Health Services Administration
SCr	serum creatinine
SJS	Stevens Johnson Syndrome
SMAC	state maximum allowable cost
SMR	sexual maturity rating
SPT	skin patch test
SQ	subcutaneous
SSRI	selective serotonin reuptake inhibitor
STI	sexually transmitted infection
STR	single-tablet regimen
SUD	substance use disorder
TasP	treatment as prevention
TB	tuberculosis
TC	total cholesterol

TCA	tricyclic antidepressant
TDM	therapeutic drug monitoring
TDR	transmitted drug resistance
TG	triglyceride
The Panel	The Panel on Antiretroviral Guidelines for Adults and Adolescents
THRIVE	Targeting HIV Retention and Improved Viral load through Engagement
U=U	Undetectable = Untransmittable
UGT	uridine diphosphate glucuronosyltransferase
UGT1	uridine diphosphate glucuronosyltransferase 1 family
UGT1A1	uridine diphosphate glucuronosyltransferase 1A1
ULN	upper limit of normal
USTS	U.S. Transgender Survey
UW	University of Washington
VL	viral load
VPA	valproic acid
WAC	wholesale acquisition cost
WBC	white blood cell
WHO	World Health Organization
WPATH	World Professional Association for Transgender Health
XDR	extensively drug resistant
XR	extended release
Zn	zinc

## Study and Trial Names

<i><b>Acronym/Abbreviation</b></i>	<i><b>Name</b></i>
ACTG	AIDS Clinical Trials Group
ADVANCE	Assessing Donor Variability And New Concepts in Eligibility
ARDENT	ACTG A5257 trial
ARTEMIS	Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
ATLAS	Antiretroviral Therapy as Long-Acting Suppression
D:A:D	Data Collection on Adverse Events of Anti-HIV Drugs
ECHO	Evidence for Contraceptive Options in HIV
ENCORE	Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy
FLAIR	First Long-Acting Injectable Regimen
FLAMINGO	Dolutegravir Compared to Darunavir/Ritonavir, Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors
HPTN	HIV Prevention Trials Network
NADIA	Nucleosides And Darunavir/Dolutegravir In Africa
NAMSAL	New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-income countries
STaR	Single-Tablet Regimen
START	Strategic Timing of AntiRetroviral Treatment